Publicaciones en las que colabora con Raúl Jiménez Agüero (20)

2023

  1. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  2. miR-21-5p promotes NASH-related hepatocarcinogenesis

    Liver International, Vol. 43, Núm. 10, pp. 2256-2274

2021

  1. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD

    Frontiers in Medicine, Vol. 8

  2. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease

    Gut, Vol. 70, Núm. 12, pp. 2359-2372

  3. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

    Gut, Vol. 70, Núm. 7, pp. 1345-1361

  4. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma: Diagnosis of NAFLD-HCC utilising serum lipidomics

    EBioMedicine, Vol. 73

2020

  1. Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

    Cells, Vol. 9, Núm. 3

  2. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2019

  1. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

    Gut, Vol. 68, Núm. 3, pp. 533-546

2018

  1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

  2. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts

    Hepatology Communications, Vol. 2, Núm. 7, pp. 807-820

  3. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

  4. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2017

  1. Molecular mechanisms of cholangiocarcinogenesis: New potential targets for therapy

    Current Drug Targets, Vol. 18, Núm. 8, pp. 932-949

  2. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

  3. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

    Hepatology, Vol. 66, Núm. 4, pp. 1125-1143

2016

  1. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery

    Surgery for Obesity and Related Diseases, Vol. 12, Núm. 10, pp. 1838-1846

2015

  1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

  2. Novel equation to determine the hepatic triglyceride concentration in humans by MRI: Diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery

    BMC Medicine, Vol. 12, Núm. 1